The ultimate ASX growth shares to buy with $2,000 in March

Analysts think these shares could be among the best of the best for growth investors.

| More on:
Ecstatic woman looking at her phone outside with her fist pumped.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of ASX growth shares for investors to choose from on the Australian share market.

To narrow things down, let's take a look at some that could be considered among the best of the best.

Here's why analysts think they could be top picks for a $2,000 investment:

Pro Medicus Limited (ASX: PME)

Pro Medicus is one of the most explosive ASX growth shares on the Australian share market.

For many years, the health imaging technology company has been growing at a rapid rate thanks to increasing demand for its Visage solution.

Bell Potter believes this strong form can continue. It said:

The PME full stack solution continues to wipe the floor with competitors – 10 contract announcements in the LTM including two new academic medical centres clients. FY25/26 revenues upgraded by 4% and 2% respectively. In addition we expect further growth in the cardiology space with the first small scale implementation to take place in April 2025.

Bell Potter has a buy rating and $330.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Goldman Sachs thinks that ResMed could be an ASX growth share to buy with $2,000.

It is a leading sleep disorder treatment company with a world class portfolio of devices and software to treat sleep apnoea and other conditions.

Sleep apnoea is a huge market, with an estimated 3 in 10 men and 1 in 5 women having the condition. And with awareness increasing thanks to technology, ResMed is in a very strong position as the clear industry leader. Goldman Sachs said:

Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook.

Goldman has a conviction buy rating and $49.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

Finally, WiseTech Global could be another ultimate ASX growth share to buy.

It is a leading global provider of software solutions to the logistics services industry with its CargoWise One platform.

WiseTech Global has been growing at a rapid rate for many years thanks to strong demand for CargoWise One. And while product launch delays and CEO indiscretions have weighed on sentiment in recent months, the future remains very bright for the company and its shares.

It is for this reason that Goldman Sachs is tipping it as a buy. It said:

We are positive on WiseTech's strong competitive position which contributes to efficiency gains for LGFF's. Over the short-to-medium term we expect WiseTech's earnings profile to benefit from new product releases such as Container Transport Optimizer, as well as the company continuing to grow penetration of their core business.

We expect WiseTech will continue to focus on product development over the long-term, which should underpin margin expansion and earnings growth. Hence, with the risk/reward profile skewed to the upside we are Buy rated.

Bell Potter currently has a buy rating and $128.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Pro Medicus, ResMed, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, ResMed, and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed and WiseTech Global. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Growth Shares

3 fantastic ASX 200 growth shares to buy with $20,000

Brokers think these shares are going places. Let's see what they are.

Read more »

a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
Growth Shares

1 magnificent ASX stock down 33% to buy and hold forever

Analysts think that this fallen angel could be a quality buy right now.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Growth Shares

Got $2,000 to invest? These ASX shares could rise 30% to 60%

Analysts are tipping these shares to rise strongly from current levels.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Growth Shares

Macquarie tips these ASX growth shares as buys

The broker is feeling bullish about these top shares. Let's see why.

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Growth Shares

5 top ASX stocks to buy now with $5,000

Analysts are recommending these stocks as top buys right now.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Growth Shares

Top ASX stocks to buy right now with $7,000

Analysts think these shares would be top picks for your money.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Growth Shares

3 excellent ASX 200 growth shares to buy and hold with $3,000

Here's why analysts think these shares could be top picks for growth investors.

Read more »

A senior couple sets at a table looking at documents as a professional looking woman sits alongside them as if giving retirement and investing advice.
Value Investing

Forecast earnings growth of 10% a year but down 11%, is now the time for me to consider this ASX 200 high-flyer?

Despite recent good news, the shares are down...

Read more »